cell therapies

RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis

ReaCT Trial at University of British Columbia Treating Patients with Autologous Cell Therapy VANCOUVER, June 30, 2015 /PRNewswire/ – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V:…